Brought to you by 
Pamplona Capital Management acquires Parexel in a take-private deal
20 Jun 2017
Executive Summary
Pamplona Capital Management agreed to acquire all of the outstanding shares of CRO Parexel International Corp. for $88.10 per share (a 6.6% premium) in an all-cash, take-private transaction.
Deal Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
- Services
Deal Status
- Final
Deal Type
-
Acquisition
- Buy-out
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pamplona Capital Management acquires Parexel in a take-private deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice